- China Taiping reported a net income of HK$6.76 billion for the first half of the year 2025.
- This reflects a 12% increase compared to the previous year’s net income of HK$6.03 billion.
- Insurance revenue was slightly up, recorded at HK$55.96 billion, showing a marginal increase of 0.2% year-over-year.
- The company’s stock analysts have given it 14 buy ratings, 2 hold ratings, and 2 sell ratings.
“`
A look at China Taiping Insurance Hldgs Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 5 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts at Smartkarma have provided an overall positive long-term outlook for China Taiping Insurance Holdings Company Ltd. based on their Smart Scores evaluation. The company has received a high score for Growth and Momentum, indicating strong potential in these areas. With a solid focus on expanding and driving forward, China Taiping Insurance Hldgs is positioned well for future development in the insurance sector.
While the company scores moderately on Value and Resilience, the higher scores in Growth and Momentum underscore the market’s belief in China Taiping Insurance Hldgs‘ ability to capitalize on growth opportunities and maintain a positive trajectory in the long term. Investors may view this as a favorable outlook for the company’s future performance and strategic positioning in the insurance industry.
Summary: China Taiping Insurance Holdings Company Ltd. operates as an insurance and reinsurance underwriter primarily for life and property/casualty insurance through its subsidiaries.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
